The Company spent $1.8m during the period on non-recurring capital items and product development, including costs relating to the FDA application for Xprecia Prime.The Company also spent $1.2m on inventory relating to new products launched in markets around the world. As this is a 4C we do not see what the receivables are so it highly likely that most of the sales made in December and possibly part of November as well (depending on terms) will not have been cash settled as of year end.
UBI Price at posting:
19.5¢ Sentiment: Buy Disclosure: Held
